Clinical trials: Neurocognitive Disorders, Mild
Alzheimer's Disease
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.
- Trial name
- EXPEDITION 3 (NCT01900665)
- Testing
- Solanezumab
- Where
- 198 sites in United States, Australia and 9 more
- Volunteers
- 2,129 people
- Sponsor
- Eli Lilly and Company
Dementia, Cognitive Impairment, Mild
Cognitive Stimulation Therapy for Dementia: A Two-Armed Pragmatic Trial
Cognitive Stimulation Therapy (CST) is an evidence-based non-pharmacological group therapy shown to benefit people with mild to moderate dementia.
- Conditions
- Dementia, Cognitive Impairment, Mild, Dementia, Vascular, Dementia, Mixed
- Trial name
- NCT05860127
- Testing
- Referral for Cognitive Stimulation Therapy, No change to Standard of Care
- Where
- 2 sites in United States
- Volunteers
- 133 people
- Sponsor
- University of Massachusetts, Amherst
Type 2 Diabetes, Mild Cognitive Impairment
Improving Medication Adherence in Older African Americans With Diabetes
This research aims to help older African Americans with diabetes and mild memory problems improve how they take their medications and control their diabetes.
- Trial name
- NCT02174562
- Testing
- Primary Care-Occupational Therapy, Enhanced Usual Care
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Thomas Jefferson University
Mild Cognitive Impairment
Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
This study is intended to investigate the safety of candesartan, a blood pressure medication, in non-hypertensive individuals who have mild cognitive impairment (MCI) due to Alzheimer's disease and its effect on disease…
- Trial name
- CEDAR (NCT02646982)
- Testing
- Candesartan
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- Emory University
Mild Cognitive Impairment, Cognitive Decline
Effects of Walkasins on Gait Speed of Individuals With Mild Cognitive Impairments
The primary aim of this pilot study is to investigate the effect of Walkasins, a wearable lower-limb sensory prosthesis, on the gait speed and balance function of participants with mild cognitive impairment as measured by the…
- Conditions
- Mild Cognitive Impairment, Cognitive Decline, Gait Disorders in Old Age
- Trial name
- NCT05723822
- Testing
- Walkasins
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- RxFunction Inc.
Mild Cognitive Impairment
Effects of Atomoxetine in Mild Cognitive Impairment
The purpose of this study is to evaluate the safety of atomoxetine and its effect primarily on the biologic markers (substances that may indicate the presence of a disease) in the cerebrospinal fluid (CSF) of participants…
- Trial name
- ATX-001 (NCT01522404)
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Emory University
Alzheimer Disease, Dementia of Alzheimer Type
A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease
This study is designed to evaluate treatment effects of ATH-1017 (fosgonimeton) in mild to moderate Alzheimer's subjects with a randomized treatment duration of 26-weeks.
- Trial name
- ACT-AD (NCT04491006)
- Testing
- ATH-1017
- Where
- 13 sites in United States, Australia
- Volunteers
- 77 people
- Sponsor
- LeonaBio
Alzheimer Disease
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
The primary objective of the study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of…
- Trial name
- NCT04971733
- Testing
- E2814
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 8 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
This Phase II, open-label extension (OLE), multicenter study will evaluate the long-term safety and tolerability of crenezumab in participants with mild to moderate Alzheimer's disease who have participated in and completed the…
- Trial name
- NCT01723826
- Testing
- Crenezumab
- Where
- 86 sites in United States, Canada and 4 more
- Volunteers
- 360 people
- Sponsor
- Genentech, Inc.
Parkinson Disease, Mild Cognitive Impairment
Mild Cognitive Impairment and Endurance Exercise in Parkinson's Disease
The overall objective of this study is to determine how high intensity endurance exercise affects both cognition and the signs and symptoms of Parkinson's disease as well as if certain brain structures and functions also change…
- Trial name
- NCT03542474
- Testing
- High Intensity Endurance Exercise
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwestern University
Alzheimer Disease, Mild Cognitive Impairment
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
This protocol is designed to standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden in subjects participating in other studies (companion protocol) such as longitudinal studies of aging…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
- Trial name
- NCT01518374
- Testing
- Florbetapir F 18
- Where
- 26 sites in United States
- Volunteers
- 1,768 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Mild Cognitive Impairment, Cognitive Decline
Brain Health Together: A Live-Streaming Group-Based Digital Program
The purpose of this study is to develop and test a comprehensive Brain Health Together program for older adults living with cognitive decline.
- Conditions
- Mild Cognitive Impairment, Cognitive Decline, Cognitive Deterioration, Cognitive Deficits, Mild
- Trial name
- NCT05818423
- Testing
- Brain Health Academy, Brain Health Together, Maintain Brain Health Together
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- University of California, San Francisco
Mild Cognitive Impairment, Dementia
Validity of the Electronic Self-Administered Gerocognitive Examination (eSAGE)
The Self-Administered Gerocognitive Examination (SAGE) is a valid and reliable cognitive assessment tool used to identify both Mild Cognitive Impairment (MCI) and early dementia.
- Trial name
- eSAGE (NCT02544074)
- Testing
- neuropsychological testing, eSAGE testing
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Alzheimer's Disease
Bexarotene Amyloid Treatment for Alzheimer's Disease
Retinoid X receptors (RXR) are nuclear receptors that have been linked to numerous metabolic pathways relevant to Alzheimer's disease (AD) and Aβ (harmful protein) production and removal.
- Trial name
- BEAT-AD (NCT01782742)
- Testing
- Bexarotene
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Cleveland Clinic
Alzheimer's Disease
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.
- Trial name
- CREAD 2 (NCT03114657)
- Testing
- Crenezumab
- Where
- 211 sites in United States, Argentina and 25 more
- Volunteers
- 806 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease
The purpose of this study is to investigate efficacy and safety of different doses of AC-3933 in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00359944
- Testing
- AC-3933, Sugar Pill
- Where
- 34 sites in United States
- Volunteers
- 171 people
- Sponsor
- Sumitomo Pharma America, Inc.
Alzheimer's Disease
Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study
This study seeks to confirm a demonstrated treatment effect of intepirdine (RVT-101) as an adjunctive therapy to donepezil for the treatment of subjects with Alzheimer's disease.
- Trial name
- NCT02585934
- Testing
- RVT-101
- Where
- 197 sites in United States, Argentina and 17 more
- Volunteers
- 1,315 people
- Sponsor
- Axovant Sciences Ltd.
Cognition
A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability
The purpose is to compare solifenacin and oxybutynin with an inactive tablet and assess any potential effects on mental ability.
- Trial name
- SENIOR (NCT01126424)
- Testing
- Solifenacin, Oxybutynin
- Where
- 3 sites in United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Chronic Pain, Mild Cognitive Impairment
Managing Pain and Cognitions in Older Adults With Mild Cognitive Impairment or Memory Related Problems and Chronic Pain
We aim to conduct a pilot randomized controlled trial comparing 2 symptom management programs for older adults with self-reported memory problems and chronic pain, Active Brains 1 and Active Brains 2.
- Conditions
- Chronic Pain, Mild Cognitive Impairment, Older Adults, Physical Activity
- Trial name
- NCT04044183
- Testing
- Active Brains 1, Active Brains 2
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
Mild to Moderate Alzheimer's Disease
NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.
To evaluate the efficacy of rivastigmine patch with 1-step titration on cognitive function measured as change from baseline to week 24 in the total score of Mini-Mental State Examination (MMSE) in mild to moderate Alzheimer's…
- Trial name
- ENA1stepswitch (NCT02703636)
- Testing
- Rivastigmine Patch
- Where
- 19 sites in Japan
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals